Aldoxorubicin in soft tissue sarcomas.

Abstract

Aldoxorubicin is a prodrug formulation of doxorubicin currently under investigation for the treatment of soft tissue sarcomas. Early studies have demonstrated a promising reduction in the cardiotoxicity of aldoxorubicin compared with equivalent doses of doxorubicin leading to an increase in the equivalent cumulative dose of aldoxorubicin. The current clinical and pharmacological data available for aldoxorubicin are extremely promising for its use in the treatment of advanced and metastatic soft tissue sarcomas compared with equivalent doses of doxorubicin although Phase III data are lacking. We review aldoxorubicin for the treatment of advanced and metastatic soft tissue sarcomas and discuss the impact it may have in the future.

• Authors: Florence E Chamberlain, Robin L Jones, Sant P Chawla
• Journal: Future oncology (London, England) (Future Oncol) Vol. 15 Issue 13 Pg. 1429-1435 (May 2019) ISSN: 1744-8301 [Electronic] England
• PMID: 30873850 (Publication Type: Journal Article, Review)

Chemical References

• Hydrazones
• Doxorubicin
• DOXO-EMCH

Topics

• Clinical Trials as Topic
• Doxorubicin (analogs & derivatives, therapeutic use)
• Humans
• Hydrazones (therapeutic use)
• Prognosis
• Sarcoma (drug therapy, secondary)
• Soft Tissue Neoplasms (drug therapy, pathology)